Custom Search Insider Trading Activity Insider Trading Activity
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Custom Search Insider Trading Activity
Updated Jan 9, 2024
Ticker
|
Company Name
|
Qty.
|
Price
|
Size ($)
|
Filing Date
|
Type
|
Δ Own
|
Own
|
Insider Names
|
Title
|
Trade Dates
|
Is Scheduled
| |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bruker Corp
| 2.38K |
—
|
—
| +31.06% | 10.03K |
Jan 5
| |||||||
Veracyte, Inc.
| -1.30K |
$26.72 | -$34,842.88 | -3.06% | 41.38K |
Jun 2
| |||||||
Veracyte, Inc.
|
0
|
$13.83 | -$558,616.60 |
—
| 42.68K |
Apr 14
| |||||||
Veracyte, Inc.
|
0
|
$14.19 | -$583,147.60 |
—
| 53.97K |
Mar 15
|
Scheduled
| ||||||
Veracyte, Inc.
| -8.99K |
$24.10 | -$216,755.40 | -14.29% | 53.97K |
Mar 2
| |||||||
Bruker Corp
|
0
|
—
|
—
|
—
|
0
| ||||||||
Veracyte, Inc.
|
0
|
$15.98 | -$705,097.52 |
—
| 62.96K |
Jan 17
|
Scheduled
| ||||||
Veracyte, Inc.
|
0
|
$19.74 | -$682,232.74 |
—
| 62.96K |
Jan 11
|
Scheduled
| ||||||
Bruker Corp
| 1.97K |
—
|
—
| +34.67% | 7.65K |
Jan 5
| |||||||
Veracyte, Inc.
| -2.04K |
$29.14 | -$59,503.88 | -3.14% | 62.96K |
Dec 2
| |||||||
Veracyte, Inc.
|
0
|
$19.67 | -$1,375,448.34 |
—
| 65K |
Dec 1
|
Scheduled
| ||||||
Veracyte, Inc.
| 11.09K |
$9.02 | $99,996.04 | +17.06% | 76.09K |
Oct 13
| |||||||
Veracyte, Inc.
| -2.04K |
$19.18 | -$39,165.56 | -3.05% | 65K |
Sep 2
| |||||||
Veracyte, Inc.
| -121.92K |
$27.56 | -$3,360,445.01 | -52.03% | 112.43K |
Aug 5 - Aug 8
| |||||||
Veracyte, Inc.
| -2.04K |
$18.23 | -$37,225.66 | -2.96% | 67.05K |
Jun 2
| |||||||
Veracyte, Inc.
| -736.00 |
$20.47 | -$15,065.92 | -0.85% | 85.95K |
May 1
| |||||||
Veracyte, Inc.
| 17.67K |
—
|
—
| +25.60% | 86.69K |
Mar 3
| |||||||
Veracyte, Inc.
| -4.52K |
$27.84 | -$125,864.64 | -6.15% | 69.02K |
Mar 2
| |||||||
Bruker Corp
| 1.84K |
—
|
—
| +47.93% | 5.68K |
Jan 5
| |||||||
Veracyte, Inc.
| 11.29K |
$8.86 | $99,993.96 | +18.13% | 73.54K |
Dec 9
| |||||||
Veracyte, Inc.
| -2.29K |
$39.22 | -$89,735.36 | -3.54% | 62.26K |
Dec 2
| |||||||
Veracyte, Inc.
| -2.60K |
$50.18 | -$130,477.62 | -1.18% | 217.48K |
Sep 17
|
Scheduled
| ||||||
Veracyte, Inc.
| -1.90K |
$50.03 | -$95,049.59 | -0.86% | 220.08K |
Sep 10
|
Scheduled
| ||||||
Veracyte, Inc.
| -2.29K |
$52.97 | -$121,195.36 | -3.42% | 64.54K |
Sep 2
| |||||||
Veracyte, Inc.
| -2.29K |
$36.07 | -$82,528.16 | -1.19% | 189.72K |
Jun 2
| |||||||
Veracyte, Inc.
| 14.06K |
$5.61 | $78,904.65 | +7.90% | 192.01K |
May 17
| |||||||
Veracyte, Inc.
| -6.32K |
$62.15 | -$392,788.00 | -3.43% | 177.95K |
Mar 2
| |||||||
Veracyte, Inc.
| 20K |
—
|
—
| +12.18% | 184.27K |
Feb 26
| |||||||
Veracyte, Inc.
| -39.49K |
$62.30 | -$2,460,102.40 | -19.38% | 164.27K |
Feb 24
| |||||||
Veracyte, Inc.
|
0
|
$28.33 | -$842,447.12 |
—
| 203.76K |
Jan 13
|
Scheduled
| ||||||
Veracyte, Inc.
|
0
|
$29.23 | -$3,896,148.67 |
—
| 203.76K |
Jan 11 - Jan 12
|
Scheduled
| ||||||
Bruker Corp
| 2.3K |
—
|
—
| +149.58% | 3.84K |
Jan 5
| |||||||
Veracyte, Inc.
| 31.31K |
$3.73 | $116,918.84 | +18.16% | 203.76K |
Dec 29
| |||||||
Veracyte, Inc.
| -1.98K |
$55.08 | -$108,838.08 | -1.13% | 172.44K |
Dec 2
| |||||||
Veracyte, Inc.
|
0
|
$25.68 | -$672,728.82 |
—
| 270.23K |
Nov 10
|
Scheduled
| ||||||
Veracyte, Inc.
|
0
|
$23.43 | -$1,457,000.00 |
—
| 220.23K |
Oct 8
|
Scheduled
| ||||||
Veracyte, Inc.
|
0
|
$19.88 | -$440,660.54 |
—
| 220.23K |
Sep 10
|
Scheduled
| ||||||
Bruker Corp
| 1.54K |
—
|
—
|
∞
| 1.54K |
Sep 3
| |||||||
Bruker Corp
|
0
|
—
|
—
|
—
|
0
| ||||||||
Veracyte, Inc.
| -1.98K |
$34.16 | -$67,500.16 | -0.89% | 220.23K |
Sep 2
| |||||||
It looks like there's no data for these filter options. Maybe you'll be interested in these options instead. | |||||||||||||
Want to view more results?
Unlock the hidden results with your Benzinga Account now. No purchase required.